权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of a new multi-modality therapy for far advanced hepatocellular carcinoma : a combined therapy of a new percutaneous local tumor ablation and a chemotherapy using subcutaneously embedded port for arterial infusion or gene therapy

开发针对晚期肝细胞癌的新型多模式疗法：新型经皮局部肿瘤消融和使用皮下嵌入端口进行动脉输注或基因治疗的化疗的联合疗法

基本信息

批准号：
10670454
负责人：
SHIINA Shuichiro
金额：
$ 1.98万
依托单位：
University of Tokyo
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
1998
资助国家：
日本
起止时间：
1998 至 2000
项目状态：
已结题

项目摘要

The aim of this study was to develop a new multi-modality therapy for far advanced hepatocellular carcinoma, which had been treated non-curatively only by transcatheter arterial embolization or supportive therapy because of wide spread of the cancer. We wanted to develop a combined therapy of a new percutaneous local tumor ablation and a chemotherapy using subcutaneously embedded port for arterial infusion or gene therapy.With regard to development of a new percutaneous tumor ablation, we have performed radio-frequency ablation(RFA)on a total of 400 cases since we introduced it in February 1999. In RFA, we can surely obtain a necrotic area of 3 cm in diameter by a 12-minute ablation. In most cases, one or two treatment sessions are enough to achieve a complete necrosis of the lesion with a safety margin, which results in a shorter hospitalization. We think more than 95% of cases treated by percutaneous tumor ablation will be treated by RFA in the near future. Thus we would like to gain more know-how to perform RFA.With regard to optimization of chemotherapy, we performed "low dose FP" chemotherapy using subcutaneously embedded port for arterial infusion and have been analyzing data to evaluate factors which contributed the chemotherapeutic efficacy. The final goal is to predict therapeutic efficacy before the treatment. To do this, we would use DNA tips in the future. We have also used a new chemotherapeutic regimen of 5-FU and interferon. We will use the regimen on more cases and evaluate its efficacy.We have used nude mice to examine usefulness and safety of a gene therapy in order to introduce it to a clinical trial. However, we have not achieved satisfactory results yet.

本研究的目的是为晚期肝细胞癌开发一种新的多模式疗法，由于癌症广泛扩散，这种癌症仅通过经导管动脉栓塞或支持疗法进行非治愈性治疗。我们希望开发一种新的经皮局部肿瘤消融术和使用皮下埋入式端口进行动脉输注或基因治疗的化疗的联合疗法。关于新的经皮肿瘤消融术的开发，自1999年2月推出以来，我们已经对总共400例进行了射频消融（RFA）。在RFA中，我们肯定可以获得 12分钟消融直径3厘米的坏死区域。在大多数情况下，一两次治疗就足以在安全范围内实现病灶完全坏死，从而缩短住院时间。我们认为在不久的将来，超过95%的经皮肿瘤消融治疗的病例将采用RFA治疗。因此，我们希望获得更多执行RFA的知识。在化疗的优化方面，我们使用皮下埋入式端口进行动脉输注进行“低剂量FP”化疗，并一直在分析数据以评估影响化疗效果的因素。最终目标是在治疗前预测治疗效果。为此，我们将来会使用 DNA 吸头。我们还使用了5-FU和干扰素的新化疗方案。我们将在更多病例中使用该方案并评估其疗效。我们使用裸鼠来检验基因疗法的有效性和安全性，以便将其引入临床试验。然而，我们还没有取得令人满意的结果。